Login to Your Account



Emisphere's Oral Heparin Fails In Phase III Against Lovenox

By Karen Young


Wednesday, May 15, 2002
Emisphere Technologies Inc. said Tuesday that its Phase III trial of oral heparin failed to show superiority to Aventis SA's injected Lovenox in preventing deep-vein thrombosis in patients undergoing total hip replacement surgery. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription